Updated: January 18, 2026
Insulin Glargine-Yfgn Shortage Update: What Patients Need to Know in 2026
Author
Peter Daggett
ChatGPT
Claude
Gemini
Overview
Semglee was discontinued December 31, 2025. Here's the full 2026 shortage update for patients on insulin glargine-yfgn — what happened, what's available now, and your next steps.
Is Insulin Glargine-Yfgn in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Insulin Glargine-Yfgn near you.
The insulin glargine-yfgn supply situation in 2026 is one of the more complex access stories in recent diabetes care history. What started as a pen shortage in early 2025 ultimately led to the full discontinuation of the Semglee brand and a major shakeup in the basal insulin market. If you rely on insulin glargine-yfgn (formerly Semglee), here's everything you need to know right now.
Current Status as of 2026
As of mid-2026, according to the American Society of Health-System Pharmacists (ASHP):
Semglee brand: Discontinued as of December 31, 2025. No new branded Semglee product is available.
Generic/unbranded insulin glargine-yfgn: Available from Civica Rx (launched Jan 1, 2026 at $45/5-pen box) and from other generic manufacturers including Winthrop. However, not all pharmacies stock these versions.
Lantus (Sanofi): Generally available but experiencing intermittent back-orders on SoloStar pens due to demand surge from displaced Semglee patients. Vials remain more consistently available.
Basaglar, Rezvoglar: Available from Eli Lilly with generally good supply.
Check live stock now.
How the Shortage Developed: A Timeline
February 2025: Biocon Biologics announced an anticipated shortage of branded and unbranded Semglee pens. Expected to resolve by early March.
March 2025: Shortage persisted beyond projected resolution. Blue Cross NC and other insurers added Lantus to formularies as emergency coverage. Patients with Semglee prescriptions were able to receive Lantus at pharmacies without new prescriptions due to interchangeability.
August 2025: Regional shortages of Semglee and insulin glargine-yfgn intensified in the Pacific Northwest and Northeast. Multiple pharmacy chains reported limited availability of pen formulations.
December 31, 2025: Biocon formally discontinued all Semglee vials and pens. This ended four years of Semglee as the first interchangeable biosimilar insulin in the US.
January 2026: Civica Rx launched unbranded insulin glargine-yfgn pens at $45/5-pen box, the lowest list price for any long-acting insulin in the US. Demand shifted heavily to Lantus, Basaglar, and generic insulin glargine products, straining those supply chains.
How This Affects You: Key Questions Answered
"My prescription says Semglee. Can I still fill it?" Since Semglee is discontinued, your pharmacist cannot fill the branded Semglee prescription. However, they can substitute an interchangeable product (Lantus or unbranded insulin glargine-yfgn) without a new prescription. Ask your pharmacist directly about the substitution options.
"Will my insurance still cover it?" Coverage depends on your specific plan. Many insurers had Semglee as their preferred insulin glargine product. Post-discontinuation, plans have been updating formularies to cover Lantus or generic insulin glargine-yfgn. Check with your insurance company or benefits portal to confirm your plan's current preferred product and any prior authorization requirements.
"I can't afford Lantus without insurance coverage. What are my options?" The Sanofi Valyou Savings Program caps Lantus at $35/month for insured and uninsured patients. The Civica Rx insulin glargine-yfgn is available at $45/5 pens ($9/pen). Eli Lilly's $35/month program also covers Basaglar.
What to Do If You Can't Find Insulin Glargine-Yfgn Near You
Ask your pharmacist about Lantus substitution (no new prescription needed — it's interchangeable).
Ask specifically for unbranded insulin glargine-yfgn (Civica Rx version) or generic vials from Winthrop.
Call your doctor's office to request a prescription for an alternative (Basaglar, Rezvoglar) if needed.
Use medfinder to check which pharmacies near you currently have insulin glargine-yfgn or interchangeable products in stock.
Looking Ahead: Is the Situation Improving?
The entry of Civica Rx into the insulin glargine-yfgn market in January 2026 is a positive development for both price and supply stability. As a nonprofit pharmaceutical company with 60+ health system members and a stated mission to prevent drug shortages, Civica brings structural resilience to the market. The biosimilar insulin glargine landscape is expanding, with more options available in 2026 than ever before — though the transition period continues to create localized access challenges. Read our savings guide for more ways to lower your cost: How to Save Money on Insulin Glargine-Yfgn in 2026.
Frequently Asked Questions
Semglee itself was discontinued rather than placed on an FDA shortage list. Generic insulin glargine-yfgn has been listed on ASHP shortage alerts since early 2025. As of July 2026, ASHP notes that generic vials and pens are available from certain manufacturers, but supply is inconsistent at the pharmacy level.
Biocon Biologics formally discontinued all Semglee (insulin glargine-yfgn) vials and pens on December 31, 2025. This was a business decision by the manufacturer, not a safety recall or FDA action.
Yes. Civica Rx launched unbranded insulin glargine-yfgn pens on January 1, 2026 at a list price of $45 for five pens — the lowest list price for any long-acting insulin in the US. Generic insulin glargine-yfgn vials and pens are also available from Winthrop and other manufacturers.
Most insurance plans have updated or are updating their formularies to cover alternative insulin glargine products. Contact your insurance company or check your plan's drug formulary to see which product is now preferred. Many plans cover Lantus, Basaglar, or generic insulin glargine-yfgn with a $0–$35 copay under the Inflation Reduction Act's insulin cap.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Insulin Glargine-Yfgn also looked for:
More about Insulin Glargine-Yfgn
Why Is Insulin Glargine-Yfgn So Hard to Find? [Explained for 2026]
How to Find Insulin Glargine-Yfgn in Stock Near You (Tools + Tips)
Alternatives to Insulin Glargine-Yfgn If You Can't Fill Your Prescription
Insulin Glargine-Yfgn Shortage: What Providers and Prescribers Need to Know in 2026
How to Help Your Patients Find Insulin Glargine-Yfgn in Stock: A Provider's Guide
How to Save Money on Insulin Glargine-Yfgn in 2026: Coupons, Discounts, and Patient Assistance
38,224 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.